Literature DB >> 7694662

Expression of adhesion molecules on acute leukemic blast cells and sensitivity to normal LAK activity.

D Raspadori1, F Lauria, M A Ventura, D Rondelli, S Tura.   

Abstract

Antigenic expression of CD54 and CD58 adhesion molecules was investigated on leukemic blast samples from ten patients with acute lymphoblastic (ALL) and 14 with acute myeloblastic (AML) leukemia. The mean intensity of fluorescence (MIF) was calculated and correlated with sensitivity of blast cells to the lytic activity of allogeneic lymphokine-activated killer (LAK) cells. CD54 antigen was expressed in all AML cases with an MIF of 11.2 while in ALL, though present in the majority of cases, it was absent in one case and expressed in less than 30% of blasts in two others, with an overall MIF of 3.0. CD58 expression was similar in both groups of patients, with an MIF of 7.6 in ALL and 7.0 in AML. In addition, in six of the ten ALL cases and in two of the 14 AML cases, leukemic blasts proved to be "resistant" to the cytotoxic activity of normal allogeneic LAK effectors. In these "LAK-resistant" patients, the CD54 antigenic expression was lower (p = 0.03) than in "LAK-sensitive" patients with an MIF of 1.7 vs 4.9 in ALL and 1.35 vs 12.9 in AML cases. Finally, blocking of CD54 and/or CD58 receptors on leukemic blasts resulted in a slight reduction of 51Cr release. Findings suggest that CD54 is differently expressed on myeloid and lymphoid blasts and that there is a correlation between CD54 MIF and susceptibility of blasts to the LAK activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7694662     DOI: 10.1007/bf01715049

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  20 in total

Review 1.  Mechanism of cytotoxicity by natural killer (NK) cells.

Authors:  R B Herberman; C W Reynolds; J R Ortaldo
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

Review 2.  Human natural killer cells: biologic and pathologic aspects.

Authors:  G Trinchieri; B Perussia
Journal:  Lab Invest       Date:  1984-05       Impact factor: 5.662

3.  Interleukin 2 and the treatment of leukemia and lymphoma.

Authors:  M K Brenner
Journal:  Leuk Lymphoma       Date:  1991

4.  Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors.

Authors:  R Foa; M T Fierro; D Raspadori; M Bonferroni; S Cardona; A Guarini; A G Tos; P F di Celle; A Cesano; L Matera
Journal:  Blood       Date:  1990-10-01       Impact factor: 22.113

5.  Resistance of leukemic blasts to lymphokine activated killer (LAK)-mediated cytotoxicity is not related to their adhesion properties.

Authors:  A K Palucka; A Porwit; P Reizenstein
Journal:  Eur J Haematol       Date:  1991-08       Impact factor: 2.997

6.  Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease.

Authors:  R Foa; M T Fierro; A Cesano; A Guarini; M Bonferroni; D Raspadori; R Miniero; F Lauria; F Gavosto
Journal:  Blood       Date:  1991-08-15       Impact factor: 22.113

7.  Adhesion characteristics of human interleukin 2-activated natural killer cells.

Authors:  R J Melder; E Walker; R B Herberman; T L Whiteside
Journal:  Cell Immunol       Date:  1991-01       Impact factor: 4.868

8.  Induction of NK cell activity against fresh human leukemia in culture with interleukin 2.

Authors:  E Lotzová; C A Savary; R B Herberman
Journal:  J Immunol       Date:  1987-04-15       Impact factor: 5.422

9.  Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells.

Authors:  K Oshimi; Y Oshimi; M Akutsu; Y Takei; H Saito; M Okada; H Mizoguchi
Journal:  Blood       Date:  1986-10       Impact factor: 22.113

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Intercellular adhesion molecule-1.

Authors:  A van de Stolpe; P T van der Saag
Journal:  J Mol Med (Berl)       Date:  1996-01       Impact factor: 4.599

Review 2.  Adhesion Deregulation in Acute Myeloid Leukaemia.

Authors:  Alicja M Gruszka; Debora Valli; Cecilia Restelli; Myriam Alcalay
Journal:  Cells       Date:  2019-01-17       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.